Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

The emergence this year of Humira biosimilars in Europe followed a period of sustained momentum around the cheaper versions of biologic drugs. The first biosimilar may have been launched in Europe ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return ...

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in ...

However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on cancer drug, Imbruvica, and a slow market growth trend for Juvederm ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...